Viyash Scientific reported robust Q3 FY26 results, with revenue reaching ₹8,584 million, up 11% YoY. EBITDA surged by 64% to ₹1,854 million, leading to an impressive EBITDA margin of 21.6%. The company also significantly reduced its net debt to LTM EBITDA ratio to 0.4x. This performance reflects the successful integration and synergy realization following the merger.
Financial Performance Highlights
Viyash Scientific demonstrated strong financial performance in Q3 FY26:
- Revenue: ₹8,584 million, an increase of 11% year-over-year.
- EBITDA: ₹1,854 million, a substantial surge of 64% compared to the previous year.
- EBITDA Margin: Improved significantly to 21.6%.
- Net Debt to LTM EBITDA: Reduced to 0.4x, indicating improved financial health.
9M FY26 Performance Overview
The company’s performance over the first nine months of fiscal year 2026 also reflects strong momentum:
- Revenue: ₹25,004 million, up by 12% year-over-year.
- EBITDA: ₹5,024 million, showcasing a growth of 58% compared to the previous year.
- EBITDA Margin: 20.1% for the nine-month period.
- Net Debt to LTM EBITDA: Maintained at a healthy level of 0.4x.
Revenue Distribution by Geography
The company experienced growth across various geographies:
- Formulations: Revenue of ₹4,809 million, up 20% YoY.
- Europe: Sales increased by 34% to ₹1,790 million.
- Emerging Markets: Growth of 19%, reaching ₹1,630 million.
- India: Sales grew by 30% to ₹401 million.
- APIs: Revenue of ₹3,658 million, up 3% YoY.
Strategic Focus and Future Outlook
Viyash Scientific is focused on several strategic initiatives to drive future growth, including:
- Companion Animals: Signed an exclusive distribution agreement with Boehringer Ingelheim, building new products and exploring partnerships.
- Farm Animals: Expanding into new markets and filling gaps in the product portfolio.
- Human Health: Leveraging manufacturing in India and developing complex generics.
- API + CDMO: Focusing on CDMO opportunities and leveraging existing capacity.
Merger Update
The merger has been approved by all regulatory authorities and is now in effect. The company’s focus is now on synergy realization for the next 12 months, with the process progressing as per estimated timelines.
Source: BSE
